ライフサイエンスコーパス: norovirus

1 , especially ones of mammalian origin (e.g., norovirus).

2 tool samples were tested for the presence of norovirus.

3 s, are also effective in vivo against murine norovirus.

4 greater understanding of the epidemiology of norovirus.

5 t and infection of some pathogens, including norovirus.

6 of mice with two distinct strains of murine norovirus.

7 of acquired immunity or innate resistance to norovirus.

8 (VLP) from the 2006 GII.4 Minerva strain of norovirus.

9 ectrode for the electrochemical detection of norovirus.

10 n aged <2 years had the highest incidence of norovirus.

11 ving, widely disseminated viruses like human norovirus.

12 ategies exploiting the high mutation rate of noroviruses.

13 nclature and molecular epidemiology of human noroviruses.

14 ion of other PoSaV strains and human SaVs or noroviruses.

15 adaptation of other sapoviruses and possibly noroviruses.

16 for future vaccine strategies against human noroviruses.

17 inhibitory activity of the compounds against norovirus 3C-like protease in enzyme and cell-based assa

18 Norovirus 3CL protease plays a vital role in viral repli

19 e-based, permeable macrocyclic inhibitors of norovirus 3CL protease.

20 ikely to be infected with genogroup II non-4 noroviruses (95% CI, 1.2-4.2) compared with nonsecretors

21 in the gut and have been shown to cure mouse norovirus, a small-animal model for HNoVs.

22 Norovirus accounts for a considerable portion of the glo

23 The high prevalence of norovirus across 8 sites in highly variable epidemiologi

24 ew strains, with the continuous need for new norovirus affinity ligands.

25 Norovirus AGE cases were 2.8-fold more likely than norov

26 ic human norovirus, and is the fastest human norovirus amplification method to date.

27 comparable to most other reported isothermal norovirus amplification methods.

28 apply the model to three diseases, measles, norovirus and influenza, to show the feasibility of its

29 could easily discriminate between the target norovirus and other interfering molecules.

30 Norovirus and rotavirus are prominent enteric viruses re

31 indicate that host genetic susceptibility to norovirus and rotavirus infection may be strain specific

32 multiple enteric viral pathogens, including norovirus and rotavirus, in both preventing and curing i

33 Enteric caliciviruses in the genera Norovirus and Sapovirus are important pathogens that cau

34 ndent RNA polymerases (RdRps) from the human norovirus and the murine norovirus (MNV) were found to p

35 ity by the HBGA blocking assay between GII.4 norovirus and the new GII.17 variant.

36 assess the evidence for the global burden of norovirus and to consider the prospects for norovirus va

37 as likely to be infected with genogroup II.4 noroviruses and 2.2 times as likely to be infected with

38 ens for Giardia, Cryptosporidium, rotavirus, norovirus, and adenovirus infections resulting from indi

39 ve point-of-care detection of epidemic human norovirus, and is the fastest human norovirus amplificat

40 Noroviruses are a diverse group of nonenveloped RNA viru

41 Noroviruses are a foremost cause of gastroenteritis outb

42 Human noroviruses are a leading cause of gastroenteritis acros

43 Human noroviruses are a leading cause of gastroenteritis world

44 Human noroviruses are a major cause of viral gastroenteritis,

45 Human noroviruses are a major global cause of disease, yet we

46 Noroviruses are members of the family Caliciviridae.

47 Noroviruses are responsible for at least 50% of all gast

48 Human noroviruses are the leading cause of epidemic and sporad

49 Noroviruses are the leading cause of food-borne gastroen

50 Human noroviruses are the main cause of viral diarrhea worldwi

51 Noroviruses are the most common cause of acute gastroent

52 Noroviruses are the most frequent cause of epidemic acut

53 Human noroviruses are the primary causative agents of acute ga

54 air sampling on the noroviruses using murine norovirus as a surrogate.

55 The Xpert Norovirus assay recently received FDA clearance for the

56 prospective and frozen specimens, the Xpert Norovirus assay showed positive percent agreement (PPA)

57 positive predictive value (PPV) of the Xpert Norovirus assay was 75% for GI-positive specimens, where

58 y, we evaluated the performance of the Xpert Norovirus assay with both fresh, prospectively collected

59 During period 2, overall AGE and norovirus-associated AGE incidence was 51.8/100 PY (95%

60 During period 1, overall diarrhea and norovirus-associated diarrhea incidence was 37.2/100 per

61 Thus, reducing norovirus-associated disease is a critical priority.

62 pportunity to estimate age-specific rates of norovirus-associated infectious intestinal disease in th

63 This study emphasises the impact of norovirus-associated infectious intestinal disease, espe

64 derstanding the burden of medically attended norovirus-attributable gastroenteritis (MA-NGE) and targ

65 Medically attended norovirus-attributable gastroenteritis hospitalization r

66 l as recent advances in our understanding of norovirus biology and pathogenesis.

67 Basic understanding of norovirus biology continues to accelerate, but parallel

68 virus (MNV) are used as models to understand norovirus biology.

69 Stool samples were tested for norovirus by reverse-transcription polymerase chain reac

70 Importantly, we also demonstrate that a norovirus can infect T cells, a previously unrecognized

71 ge of innate susceptibility to rotavirus and norovirus can lead to improved understanding of both vac

72 Noroviruses can establish chronic infections with active

73 Noroviruses can infect individuals who had been previous

74 led that the protruding domain of the murine norovirus capsid protein VP1, specifically residue 296 o

75 Vomiting without diarrhea occurred among norovirus cases in participants <15 years old, but with

76 sulted in a 20% improvement for detection of norovirus cases.

77 s in vitro (5-7) , efforts to define in vivo norovirus cell tropism have generated conflicting result

78 e most extensive analyses to date of in vivo norovirus cell tropism in orally inoculated, immunocompe

79 norovirus proteases upon cleavage of various norovirus cleavage sites inserted into a linker region s

80 ctive, as demonstrated by an analysis of 555 Norovirus complete genomes and 2500 sequence fragments,

81 The genus Norovirus comprises large genetic diversity, and new GII

82 aptasensor was employed to detect a range of norovirus concentration.

83 group), and 8 had diarrhea in the absence of norovirus (control group).

84 multiple affinity ligands for future use in norovirus detection and possible therapeutic development

85 Difficulties encountered were low norovirus disease rate, and inability to define illness

86 terize the viral and host characteristics of norovirus disease.

87 nued efforts to reduce the overall burden of norovirus disease.

88 e infection (13.3% and 11.8%, respectively), norovirus enteritis (8.2% and 3%), cytomegalovirus disea

89 Data on norovirus epidemiology among all ages in community setti

90 longitudinal, multicountry study describing norovirus epidemiology during the first 2 years of life.

91 rtant gaps in scientific knowledge regarding norovirus, especially with respect to disease in low-inc

92 recombination is an important mechanism for norovirus evolution and a phenomenon that was shown to o

93 ed the ability of these synbodies to capture norovirus from dilute solutions and found that one synbo

94 Norovirus full-genome sequencing is challenging due to s

95 usually self-limiting, in the United States norovirus gastroenteritis causes an estimated 56,000 to

96 Norovirus gastroenteritis is a major public health burde

97 ility to infections, including Rotavirus and Norovirus Gene-set enrichment analysis suggested pathway

98 sive E. coli (OR: 1.65; 95% CI: 1.10, 2.46), norovirus genogroup I (OR: 1.66; 95% CI: 1.23, 2.25), an

99 Rotavirus, norovirus genogroup II, Cryptosporidium, and Shigella sp

100 tanding of protein function within different Norovirus genogroups and expands a growing knowledge bas

101 nce for the detection and differentiation of norovirus genogroups I and II (GI and GII), which accoun

102 ties of the NoV NS3 proteins among the seven Norovirus genogroups.

103 Norovirus genomes are enriched from stool RNA extracts t

104 Norovirus genomes are frequently detected in the air of

105 s accommodating sequence heterogeneity among norovirus genomes.

106 r Shigellaspp.,Campylobacterspp., rotavirus, norovirus genotype 1/2 (GI/GII), and adenovirus compared

107 Norovirus genotype GII.4 has been reported to be most pr

108 previously exposed to the same or different norovirus genotypes.

109 up II, genotype 4 (GII.4) cluster within the Norovirus genus.

110 A marker AllBac, four human enteric viruses (norovirus GI and II, enterovirus and group A rotavirus)

111 ear-olds received 2 injections of placebo or norovirus GI.1/GII.4 bivalent vaccine-like particle (VLP

112 gh log removals for adenovirus (3.9 to 5.5), norovirus GII (4.6 to 5.7), and F+ coliphage (5.4 to 7.1

113 Norovirus GII (AF 5.2%, 95% CI 3.0-7.1), rotavirus (4.8%

114 confidence interval (CI): 1.21, 470.14) and norovirus GII + enteroaggregative E. coli (OR = 3.06, 95

115 icant negative interaction was found between norovirus GII + typical enteropathogenic E. coli (OR = 0

116 is study were to investigate the presence of norovirus GII bioaerosols during gastroenteritis outbrea

117 i, Shigella, Campylobacter, Cryptosporidium, norovirus GII, and adenovirus.

118 Norovirus GII, Cryptosporidium, Shigella, ST-ETEC, and a

119 de over 4 logs of removal for adenovirus and norovirus GII, even after a partial loss of the cake lay

120 The rapid identification of norovirus has important implications for infection preve

121 main poorly understood, with most studies of noroviruses having focused on serological responses to i

122 tive of this study was to characterize human norovirus (hNoV) GI and GII reductions during disinfecti

123 mediated antiviral activity.IMPORTANCE Human noroviruses (HNoVs) are the leading cause of epidemic ga

124 gnotobiotic facility and evaluated for human norovirus (HuNoV) infection.

125 Human noroviruses (HuNoVs) are a leading cause of epidemic gas

126 Human noroviruses (HuNoVs) are a leading cause of foodborne di

127 Human noroviruses (HuNoVs) are positive-sense RNA viruses that

128 Human noroviruses (HuNoVs) are the leading cause of epidemic g

129 Human noroviruses (HuNoVs) cause sporadic and epidemic gastroe

130 lopment of effective interventions for human noroviruses (HuNoVs) has been the lack of a robust and r

131 Human noroviruses (HuNoVs), named after the prototype strain N

132 s-host interaction, and replication of human noroviruses (huNoVs).

133 rrhea and acute gastroenteritis (AGE) due to norovirus in a lower-middle-income community.

134 used for point-of-care one-step detection of norovirus in clinical samples.

135 The assay also detected norovirus in directly boiled stool, and displayed better

136 ver, the data supporting the precise role of norovirus in low- and middle-income settings are sparse.

137 The assay detected norovirus in some samples in as little as 6 min, and the

138 of aptasensor was also assessed by detecting norovirus in spiked blood samples.

139 rticles in this supplement is that burden of norovirus in the United Kingdom and elsewhere is substan

140 The cellular tropism of noroviruses in immune-competent hosts remains enigmatic.

141 teroids can all support infection of certain noroviruses in vitro (5-7) , efforts to define in vivo n

142 Norovirus incidence was compared between severe combined

143 Continued molecular surveillance of noroviruses, including typing of both polymerase and cap

144 article, I discuss our recent work on murine norovirus indicating that an animal virus in the intesti

145 ca microbeads zones to filter and enrich the norovirus infected clinical sample.

146 rt showing a positive association of chronic norovirus infection and secondary LM.

147 FUT2 status is associated with norovirus infection and varies by ancestry.

148 The mechanisms of diarrhea in chronic norovirus infection are not well understood, but in anal

149 ites, 89% of children experienced at least 1 norovirus infection before 24 months, and 22.7% of all d

150 Norovirus infection constitutes the primary cause of acu

151 A total of 66% of children had at least 1 norovirus infection during the first 3 years of life, an

152 A new system for reporting outbreaks of norovirus infection in hospitals, the Hospital Norovirus

153 IIIb strains emerged as the leading cause of norovirus infection in select global locations.

154 Chronic norovirus infection is an emerging challenge in the immu

155 Thus, norovirus infection of B cells may directly contribute t

156 This period saw >1800 outbreaks of norovirus infection reported in hospitals in England, af

157 Norovirus infection was confirmed using quantitative pol

158 Of these, 7 had chronic symptomatic norovirus infection with diarrhea (noro group), and 8 ha

159 plant recipients who had symptomatic chronic norovirus infection with diarrhea were asked to particip

160 rnutrition was a risk factor for symptomatic norovirus infection, with an increase in 1 standard devi

161 therapeutics available for the management of norovirus infection.

162 60% of B+ and 63% of B- patients developed norovirus infections therefore norovirus replication in

163 Previous norovirus infections were not associated with the risk o

164 vailable for the treatment or prophylaxis of norovirus infections.

165 2017) and Tomov et al. (2017) determine that norovirus innate immune evasion enables infection of int

166 at the dominant cellular targets of a murine norovirus inoculated orally into immunocompetent mice ar

167 Human norovirus is a leading cause of viral gastroenteritis wo

168 Human norovirus is a member of the Caliciviridae family respon

169 Human norovirus is a significant public health burden, with >3

170 Norovirus is an important cause of childhood diarrhea.

171 Norovirus is an important cause of gastroenteritis in he

172 Norovirus is an important pathogen in a number of high-p

173 Although norovirus is an intestinal pathogen, aerosols could, if

174 Globally, norovirus is associated with approximately one-fifth of

175 Surveillance for norovirus is challenging because the nature of illness d

176 Routine testing for norovirus is seldom undertaken, and diagnosis is mainly

177 lenging because the nature of illness due to norovirus is such that the majority of people who are in

178 Norovirus is the leading cause of community-acquired and

179 Although norovirus is the most common cause of gastroenteritis, t

180 Norovirus is the most common cause of outbreaks of acute

181 Norovirus is the most common cause of sporadic gastroent

182 block glycan binding of four pandemic GII.4 noroviruses isolated in the last 4 decades.

183 , as an important factor required during the norovirus life cycle.

184 of IFN-lambda in resolving persistent murine norovirus (MNoV) infection and regulates fecal shedding

185 beta prevented the systemic spread of murine norovirus (MNoV), only IFN-lambda controlled persistent

186 Using murine norovirus (MNoV), we determine that a small number of in

187 also presented for surrogate viruses murine norovirus (MNV) and bacteriophage MS2 under identical ex

188 acy of PAA and monochloramine against murine norovirus (MNV) and MS2 bacteriophage in secondary efflu

189 Feline calicivirus (FCV) and murine norovirus (MNV) are used as models to understand norovir

190 Studies on the related murine norovirus (MNV) have demonstrated the importance of an i

191 Studies on murine norovirus (MNV) have shown the importance of an interfer

192 In contrast, murine norovirus (MNV) infection did not impact arsenite-induce

193 However, recent work in the murine norovirus (MNV) model of persistent infection demonstrat

194 Using the murine norovirus (MNV) model, we have recently identified a net

195 This study reveals that murine norovirus (MNV) NS3 is intimately associated with the vi

196 Using two murine norovirus (MNV) strains to model coinfection, we develop

197 used genetically engineered strains of mouse norovirus (MNV) to investigate CD8(+) T cell differentia

198 feron-gamma (IFNG) disrupts the RC of murine norovirus (MNV) via evolutionarily conserved autophagy p

199 Rps) from the human norovirus and the murine norovirus (MNV) were found to preferentially recognize R

200 jor and minor capsid proteins, but in murine norovirus (MNV), the subgenomic RNA also encodes the VF1

201 opathogenic Escherichia coli (EPEC, n = 21), norovirus (n = 21), rotavirus (n = 15), sapovirus (n = 9

202 rus AGE cases were 2.8-fold more likely than norovirus-negative controls to be secretors (P < .001) i

203 Norovirus (NoV) infections are a significant health burd

204 Norovirus (NoV) is a major cause of gastroenteritis and

205 The emergence of pandemic GII.4 norovirus (NoV) strains has been proposed to occur due t

206 Norovirus (NoV) that enters drinking water sources with

207 The capacity of human norovirus (NoV), which causes >90% of global epidemic no

208 Knowledge of the fate of human noroviruses (NoV) in the marine environment is key to be

209 Noroviruses (NoVs) are a leading cause of gastroenteriti

210 Noroviruses (NoVs) are highly prevalent, positive-sense

211 Noroviruses (NoVs) are prevalent pathogens that infect t

212 Human noroviruses (NoVs) are the main etiological agents of ac

213 cades of pandemic GII.4 NoV.IMPORTANCE Human noroviruses (NoVs) are the major cause of acute gastroen

214 Human noroviruses (NoVs) are the primary cause of acute gastro

215 enteric virus infection in vivo Upon murine norovirus or reovirus infection, Ifnlr1 depletion in IEC

216 F model, using 21 years of environmental and norovirus outbreak data collected from Louisiana oyster

217 rovirus infection in hospitals, the Hospital Norovirus outbreak Reporting Scheme (HNORS), began in Ja

218 Modeling and prediction of oyster norovirus outbreaks along Gulf of Mexico coast.

219 The ability to predict oyster norovirus outbreaks at their onset may make it possible

220 le to prevent or at least reduce the risk of norovirus outbreaks by closing potentially affected oyst

221 rted 2 outbreaks, and hospital E reported 16 norovirus outbreaks during this period.

222 e NORF model predicted all historical oyster norovirus outbreaks from 1994 through 2014.

223 r confirmation, but they suggest that oyster norovirus outbreaks may be predictable using the NORF mo

224 Specifically, norovirus outbreaks occurred when the NORF model probabi

225 Oyster norovirus outbreaks often pose high risks to human healt

226 matical model for predicting risks of oyster norovirus outbreaks using environmental predictors.

227 We found that the model-based probability of norovirus outbreaks was most sensitive to gage height (t

228 controls, and 18 nonexposed controls from 10 norovirus outbreaks were enrolled.

229 Norovirus outbreaks were investigated during a 3-month e

230 tember 2013 and August 2016, 2,715 genotyped norovirus outbreaks were submitted to CaliciNet.

231 a newer infrastructure (B), which reported 2 norovirus outbreaks, demonstrated that 7 bed-days had be

232 ties (LTCFs) are the most common setting for norovirus outbreaks.

233 genetic host factors of naturally occurring norovirus outbreaks.

234 l infection pattern of one reported inflight norovirus outbreaks.

235 ndered by the limited understanding of basic norovirus pathogenesis and cell tropism.

236 ificantly advance our basic understanding of norovirus pathogenesis.

237 tially critical role for B cell infection in norovirus pathogenesis.

238 to that pathogen has decreased markedly, but norovirus persists and is now the most common cause of p

239 Noroviruses pose a significant public health risk, parti

240 re GII.4 from a 200 000-fold dilution from a norovirus positive stool sample.

241 nths, and 22.7% of all diarrheal stools were norovirus positive.

242 ase, and 11% of control stool samples tested norovirus positive.

243 Severity of norovirus-positive diarrhea was comparable to other ente

244 were used to sequence full genomes from 507 norovirus-positive stool samples with reverse transcript

245 Norovirus prevalence in the prospective specimens (colle

246 sor to investigate the activity of different norovirus proteases upon cleavage of various norovirus c

247 Norovirus publication trends are also described using da

248 This study is the first to examine norovirus recombination following coinfection of an anim

249 his study is the first to detect and analyze norovirus recombination in an animal model.

250 anthropic funders across both countries, and norovirus-related research was identified from study tit

251 nts developed norovirus infections therefore norovirus replication in B lymphocytes is not essential

252 the identification of compounds that inhibit norovirus replication in vitro and, at least in some cas

253 mediated sterilizing immunity against murine norovirus requires the capacity of IECs to respond to IF

254 trends in US and United Kingdom funding for norovirus research clearly demonstrate insufficient tran

255 We analyzed the focus and type of norovirus research funding awarded to institutions in th

256 discoveries emanating from basic studies in norovirus research have resulted in the identification o

257 nal or international investments relating to norovirus research is limited.

258 US and United Kingdom funding investment for norovirus research was pound97.6 million across 349 awar

259 The interaction of aptamer and norovirus resulted in a decrease in the electrochemical

260 The assay successfully detected purified norovirus RNA from multiple patient outbreak isolates an

261 teract with the 5' and 3' extremities of the norovirus RNA genome.

262 ew insights into the molecular mechanisms of norovirus RNA synthesis and the sequences that determine

263 ese, 129 (9.4%) demonstrated the presence of norovirus RNA.

264 titis B and C viruses, herpes simplex virus, norovirus, rotavirus, parvovirus, and Epstein-Barr virus

265 include major human pathogens (retroviruses, noroviruses, rotaviruses, astroviruses, picornaviruses,

266 was codetected with Clostridium perfringens, norovirus, sapovirus, parechovirus, and anellovirus in 3

267 are complementary to all publicly available norovirus sequences, with multiple baits targeting each

268 Norovirus specific aptamer was tagged with a ferrocene m

269 There are currently no vaccines or norovirus-specific antiviral therapeutics available for

270 related to the discovery and development of norovirus-specific small-molecule therapeutics as well a

271 ny mechanisms involved in the replication of norovirus still remain unclear, including the role for t

272 -RPA assay targeting a recent epidemic human norovirus strain (GII.4 New Orleans) was developed and e

273 virulence on an otherwise attenuated murine norovirus strain.

274 strates that the specific recognition of the norovirus subgenomic promoter is through binding by the

275 ing that the stem-loop forms the core of the norovirus subgenomic promoter.

276 structure that functions as the core of the norovirus subgenomic RNA promoter in cells and in vitro.

277 To date, the mechanism of norovirus subgenomic RNA synthesis has not been characte

278 ntries contributed 7077 diarrheal stools for norovirus testing.

279 zed its antigenic relatedness with the GII.4 noroviruses that have dominated in China for decades.

280 Norovirus, the leading global cause of gastroenteritis,

281 There is an urgent need for norovirus therapeutics, particularly for chronic infecti

282 g with sequential GII.4 variants has allowed noroviruses to evade previously elicited antibodies, thu

283 esistance to aerosolization stress of murine norovirus type 1 (MNV-1) bioaerosols was also tested in

284 ts of aerosolization and air sampling on the noroviruses using murine norovirus as a surrogate.

285 ectin from Ralstonia solanacearum, and human norovirus VA387 P particle (24-mer of the protruding dom

286 Host genetics and pre-exposure history shape norovirus vaccine Ab responses, including blockade Ab av

287 norovirus and to consider the prospects for norovirus vaccine development.

288 ility, and the group considered how to bring norovirus vaccines from their current state of developme

289 A novel GII.17 norovirus variant caused major gastroenteritis epidemics

290 using 4 VLPs that represent different GII.4 norovirus variants identified between 1987 and 2012.

291 ccination with a multivalent GI.1 and GII.4c norovirus virus-like particle (VLP) vaccine candidate ad

292 We assessed 2 bivalent norovirus virus-like particle (VLP) vaccine candidate fo

293 on dots' (CDots) antiviral activity to human norovirus virus-like-particles (VLPs), GI.1 and GII.4 VL

294 Norovirus was a significant cause of AGE in this communi

295 Selective detection of norovirus was accomplished by functionalizing the graphe

296 Norovirus was detected in 302 of 1465 (21%) AGE cases an

297 h a detection range from 100 pM to 3.5nM for norovirus was obtained.

298 1) in the odds of experiencing diarrhea when norovirus was present, after accounting for genogroup, r

299 Noroviruses were identified in 7% (23/335) of controls f

300 , the observed antiviral effects of CDots on noroviruses were mainly through the effective inhibition

301 was enriched by hybridization with a custom norovirus whole-genome RNA bait set and deep sequenced o